Bryan B. Fuller, Founder & CEO
Dr. Fuller received his B.S. degree from The University of Michigan and his Ph.D. in Cell Biology and Biochemistry from the University of Arizona specializing in molecular endocrinology. Dr. Fuller was a professor in the Department of Biochemistry and Molecular Biology at the University of Oklahoma Health Science Center for over 20 years until he recently retired to devote his full energies to DermaMedics. He still retains an Adjunct Professor position at OUHSC and continues to teach medical students.
For over 25 years, Dr. Fuller has conducted research on the structure and function of human skin. He is one of the leaders in the field of human skin pigmentation and has done extensive research to determine how hormones and sunlight alter the growth and pigmentation in both normal human skin melanocytes and in melanoma, a deadly form of skin cancer. His discovery of hormones and hormone-like chemicals that can stimulate pigment synthesis in human skin and those that can inhibit pigmentation and therefore lighten skin has resulted in the issuance of 11 U.S. patents as well as 5 additional patent applications and additional international patents.
In addition to his research on human pigmentation, Dr. Fuller has spent many years investigating the cellular events involved in skin inflammation and inflammatory diseases. Research in his laboratory has focused on identifying novel botanically-derived chemicals for use in topical therapeutics to treat inflammatory skin conditions. This work has led to the development and commercialization by two international skin care companies of clinically tested topical skin care products that contain natural ingredients that are effective in reducing skin inflammation.
Dr. Fuller has conducted research and has served as a consultant to many skin care companies including Johnson & Johnson, Procter and Gamble, Unilever, Upjohn, Nu Skin, and Wella. His research has received support from the NIH, NSF, Procter and Gamble, and Wella, AG. Dr. Fuller has authored numerous peer-reviewed scientific articles on pigmentation and inflammation, as well as additional articles and reviews on the development of topical products for regulating pigmentation and controlling inflammation. Dr. Fuller sits on the Editorial Board of the Journal of Cosmetic Dermatology and is a member of 5 professional societies including the American Academy of Dermatology, the American Society for Biochemistry and Molecular Biology, the Society of Investigative Dermatology, the American Society for Cell Biology, the PanAmerican Society for Pigment Cell Research, and the Endocrine Society.
Dr. Fuller's vision for DermaMedics is to create a different kind of skin care company; one that utilizes the most advanced molecular biology research techniques available to identify novel botanically-derived "actives" to treat inflammatory skin problems and skin aging. These ingredients are then incorporated into topical skin therapeutics and tested to make sure that they perform at a pharmaceutical level of efficacy. Dr. Fuller's goal is to build DermaMedics into an internationally recognized company that produces patented and proprietary pharmaceutical quality therapeutic products. The proprietary products already developed by DermaMedics have been shown to work rapidly to improve skin appearance and they outperform any competitor product on the market.